Terug

Top Glove Corporation Bhd.

Datakwaliteit: 100%

TGLVY

OTC Healthcare Medical - Instruments & Supplies

€ 0,48

€ 0,00 (0,00%)

Marktkapitalisatie: 954,14M

Dagbereik

€ 0,48 € 0,52

52-Weeksbereik

€ 0,46 € 0,88

Volume

2.100

50D / 200D Gem.

€ 0,56 / € 0,58

Vorige Slotkoers

€ 0,48

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (627 peers)

Metriek	Aandeel	Sector Mediaan
P/E	7,2	0,4
P/B	0,2	2,9
ROE %	2,5	3,7
Net Margin %	3,8	3,9
Rev Growth 5Y %	-32,0	10,0
D/E	0,2	0,2

Koersdoel Analisten

Geen analistendekking beschikbaar

Winstschattingen

Periode	WPA Sch.	Omzet Sch.	Analisten
FY2027	€ 0,00 € 0,00 – € 0,00	4,4 B	0
FY2026	€ 0,00 € 0,00 – € 0,00	4,1 B	0

Belangrijkste Punten

Revenue declined -32,04% annually over 5 years

ROE of 2,50% is below average

Debt/Equity of 0,18 — conservative balance sheet

Generating 156,31M in free cash flow

P/E of 7,22 — trading at a low valuation

Revenue growth is accelerating — 1Y growth exceeds 5Y average by 70,82%

Groei

Revenue Growth (5Y)

-32,04%

Revenue (1Y)38,78%

Earnings (1Y)N/A

FCF Growth (3Y)N/A

Kwaliteit

Return on Equity

2,50%

ROIC1,19%

Net Margin3,79%

Op. Margin2,55%

Veiligheid

Debt / Equity

0,18

Current Ratio2,75

Interest Coverage17,42

Waardering

P/E Ratio

7,22

P/B Ratio0,20

EV/EBITDA16,92

Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y)	38,78%	Revenue Growth (3Y)	24,33%
Earnings Growth (1Y)	N/A	Earnings Growth (3Y)	N/A
Revenue Growth (5Y)	-32,04%	Earnings Growth (5Y)	-63,88%
Profitability
Revenue (TTM)	3,49B	Net Income (TTM)	132,18M
ROE	2,50%	ROA	2,11%
Gross Margin	2,55%	Operating Margin	2,55%
Net Margin	3,79%	Free Cash Flow (TTM)	156,31M
ROIC	1,19%	FCF Growth (3Y)	N/A
Safety
Debt / Equity	0,18	Current Ratio	2,75
Interest Coverage	17,42	Dividend Yield	0,00%
Valuation
P/E Ratio	7,22	P/B Ratio	0,20
P/S Ratio	0,27	PEG Ratio	-0,16
EV/EBITDA	16,92	Dividend Yield	0,00%
Market Cap	954,14M	Enterprise Value	1,51B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	3,49B	2,51B	2,26B	5,57B	16,36B
Net Income	132,18M	-18,27M	-878,61M	275,73M	7,76B
EPS (Diluted)	0,05	-0,03	-0,48	0,11	3,84
Gross Profit	89,01M	265,32M	64,32M	953,38M	11,10B
Operating Income	89,01M	-182,55M	-532,62M	354,87M	10,03B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Total Assets	6,27B	6,96B	7,06B	8,12B	9,78B
Total Liabilities	1,49B	1,12B	1,14B	1,32B	2,56B
Shareholders' Equity	4,76B	5,81B	5,89B	6,75B	7,17B
Total Debt	849,86M	422,09M	581,85M	417,07M	482,38M
Cash & Equivalents	298,39M	282,84M	279,77M	433,44M	875,20M
Current Assets	1,45B	1,83B	1,69B	2,11B	4,35B
Current Liabilities	528,78M	949,80M	923,87M	996,49M	2,20B

Strategiescores

This stock passed the criteria for 4 strategies

Score = fit strength (0–100)

Rank = position among all matches

Custom Cash Flow Compounder

#477 of 1052

Custom Deep Value Investing (Seth Klarman)

#457 of 824

Growth Price/Sales Ratio Focus (Ken Fisher)

#85 of 618

Value Defensive Investing (Benjamin Graham)

#92 of 710

Recente Activiteit

Ingestapt Cash Flow Compounder

Mar 24, 2026

Ingestapt Deep Value Investing (Seth Klarman)

Mar 24, 2026

Ingestapt Price/Sales Ratio Focus (Ken Fisher)

Mar 24, 2026

Ingestapt Defensive Investing (Benjamin Graham)

Mar 24, 2026